FDA Approves Injectable Form Of Glaxo's Benlysta
July 21 2017 - 9:33AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) Friday said it received
U.S. Food and Drug Administration approval for a new
self-injectable form of Benlysta, a treatment for the immune system
disease systemic lupus erythematosus.
Glaxo also said Friday that it has submitted an EU filing for
the use of its drug Relvar Ellipta in patients with Asthma.
Shares at 1300 GMT, down 2 pence, or 0.15%, at 1,623 pence
valuing the company at GBP79.8 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
July 21, 2017 09:18 ET (13:18 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024